Clinical reference Biomarker Directory
Back to directory

LCN2

Emerging

LCN2/NGAL is a promising early acute kidney injury marker, rising faster than creatinine after kidney insult.

Also known as NGAL lipocalin-2
In plain language

NGAL/lipocalin-2 rises very early after kidney damage, faster than the standard creatinine test, making it a promising early-warning marker for kidney injury — though it hasn't yet become as routine a test as troponin is for heart damage.

Biomarker & context

Lipocalin-2 (LCN2), also called neutrophil gelatinase-associated lipocalin (NGAL), is a protein released by kidney tubular cells and neutrophils in response to injury or inflammation.

What it indicates

NGAL is one of the most-studied early biomarkers for acute kidney injury (AKI), rising faster than creatinine after kidney insult, offering a potential earlier warning window than traditional kidney function tests.

Diagnosis & clinical testing

Measured via serum or urine immunoassay; despite strong research evidence, NGAL hasn't yet been universally adopted into routine clinical AKI diagnostic criteria the way troponin has for cardiac injury, reflecting ongoing questions about standardization and clinical actionability.

Guiding treatment

In research and select clinical settings, early NGAL elevation may prompt closer monitoring or earlier nephroprotective measures before creatinine rises, though this isn't yet standard practice everywhere.

Clinical significance

Not yet universally adopted into routine clinical AKI diagnostic criteria despite strong supporting research.

References
  1. General nephrology reference literature on NGAL as an early acute kidney injury biomarker.